August 8, 2025 — Edesa Biotech, Inc. (Nasdaq:EDSA) reported its financial results for the three and nine months ended June 30, 2025, and provided a business update. The clinical-stage biopharmaceutical company is focused on developing host-directed therapeutics for immuno-inflammatory diseases.
During the quarter, Edesa advanced manufacturing activities to support U.S. regulatory approval for a Phase 2 study of EB06, an anti-CXCL10 monoclonal antibody, in patients with moderate-to-severe nonsegmental vitiligo. The company anticipates submitting drug manufacturing data for EB06 to the FDA by the end of 2025.
According to CEO Par Nijhawan, Edesa is energized by the opportunity to bring an innovative immunotherapy like EB06 into an area of high unmet need. CFO Peter Weiler reported that financial results were in line with expectations, reflecting the refocusing of resources to the vitiligo development program.
Total operating expenses for the three months ended June 30, 2025, were $1.9 million. The company reported a net loss of $1.7 million, or $0.25 per common share, for the quarter ended June 30, 2025. At June 30, 2025, Edesa had cash and cash equivalents of $12.4 million and working capital of $12.1 million.
Edesa management will participate in the Canaccord Genuity 45th Annual Growth Conference and the H.C. Wainwright 27th Annual Global Investment Conference in August and September, respectively.
Contact: Gary Koppenjan, Edesa Biotech, Inc., investors@edesabiotech.com
Source: Edesa Biotech, Inc.
